Coronavirus, page-75

I am not sure whether we have covered this connection on any of the CSL discussion threads or not, but it might help to explain the continued interest in CSL and its resilient share price.

Back on the 7 Jan 2020:
SAB Biotherapeutics Announces Research Collaboration With CSL Behring
https://sabbiotherapeutics.com/2020/01/07/post-2/

Extracts:
"SAB has developed a unique platform, through advanced genetic engineering, to naturally and rapidly produce large amounts of human antibodies without using human donors."

"The agreement includes a research program which will investigate a potential new source for human immunoglobulin G (IgG). Human IgG is currently used for a number of immunological and neurological diseases including Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), and Multifocal Motor Neuropathy (MMN)."

“SAB Biotherapeutics has developed a very interesting and novel platform for the production of human immunoglobulins,” said Dr. Andrew Nash, Senior Vice President, Research for CSL Behring. “CSL Behring is committed to the continuous development of innovative therapies that address unmet needs for patients with rare and serious diseases. This collaboration will provide both companies an opportunity to explore the potential of these new approaches to positively impact areas of need.”

“We are excited that CSL Behring has chosen to work with SAB Biotherapeutics to explore new immunotherapies leveraging our technology platform,” said Dr. Eddie J. Sullivan, president, CEO and co-founder of SAB Biotherapeutics. “We believe combining our unique human antibody development and production capabilities with CSL Behring’s established immunoglobulin franchise and vast expertise in biopharmaceutical development will broaden therapeutic possibilities.”

"CSL Behring and SAB will share research program and related costs and plan to complete the initial phase in 2020. The collaboration may lead to subsequent development and commercialization agreements."

---------------------

From Twitter today (8 April 2020):
https://twitter.com/sabbantibody?lang=en

Image of two recent articles in April where SAB Bio has been engaged to work on COVID-19:



---------------------

CSL News dated 6 April 2020 in relation to it role re COVID-19 - refer to my previous post above:
https://www.csl.com/news/2020/covid-19-csl-facts

Extract:
"Evaluating potential treatment candidates with SAB Biotherapeutics, a clinical-stage biopharmaceutical company, as part of the company’s previously announced collaboration to investigate new therapies to treat infectious diseases as well as immunological and neurological conditions."

Is there a connection between this and the above twitter articles.

-----------------

Some thoughts:
- CSL is well connected and participating in potential COVID-19 on several fronts
- CSL has partnered with BARDA for other vaccine initiatives in the past
- SAB Bio's IP: "novel platform for the production of human immunoglobulins" - what can CSL leverage here to be less reliant on human blood donations

Good luck to all.